herpes simplex keratitis
Recently Published Documents


TOTAL DOCUMENTS

352
(FIVE YEARS 40)

H-INDEX

32
(FIVE YEARS 3)

2021 ◽  
Vol 25 ◽  
pp. 101105
Author(s):  
MJ Vicente Altabás ◽  
B Arias-Peso ◽  
MA Vicente Altabás

2021 ◽  
Vol 14 (9) ◽  
pp. e245792
Author(s):  
James Richardson-May ◽  
Alice Rothwell ◽  
Mohammed Rashid

An 82-year-old man with a history of herpes simplex keratitis 40 years previously presented with recurrence, 1 day following vaccination for novel COVID-19. His condition worsened despite topical treatment with ganciclovir gel. A diagnosis of herpetic stromal keratitis was made, requiring systemic aciclovir, topical prednisolone, moxifloxacin and atropine, and oral doxycycline. He improved clinically on treatment, with some residual corneal scarring. Visual acuity improved from 6/36 corrected at presentation, to 6/24 following treatment. Clearly, public and personal health benefits from vaccination are hugely important and we would not suggest avoiding vaccination in such patients. It is, however, important for ophthalmic providers to be aware of the rare potential for reactivation of herpetic eye disease following vaccination to enable prompt diagnosis and treatment.


2021 ◽  
pp. 1-3
Author(s):  
Stephan Johannes Linke

Das Review von Moshifar M et al. untersucht Fälle von Reaktivierung einer Herpes-simplex-Keratitis (HSK) nach refraktiven Operationen. Die Autoren kommen zu dem Schluss, dass HSK in der Patientenvorgeschichte nicht per se ein Ausschlusskriterium für refraktive Hornhautoperationen ist, solange sie keine aktive Infektion aufweisen und seit mindestens einem Jahr krankheitsfrei sind. Für diese Patienten empfehlen sie eine Behandlung zwei Wochen vor und mindestens zwei Wochen nach dem Eingriff mit 400 mg Acyclovir zweimal täglich oder 500 mg Valacyclovir einmal täglich.


2021 ◽  
pp. 112067212110195
Author(s):  
Carmen Alejandra Porcar Plana ◽  
Jaime Matarredona Muñoz ◽  
Jaime Moya Roca ◽  
Ezequiel Campos Mollo

Introduction: Moraxella nonliquefaciens ( M. nonliquefaciens) is a low pathogenicity microorganism, which rarely causes ocular infections, unless there is a predisposing factor. The main clinical manifestation of M. nonliquefaciens ocular infections is endophthalmitis and only five cases of corneal infection have been reported. This work shows an update in M. nonliquefaciens corneal infections, and the first reported case of keratitis due to M. nonliquefaciens superinfecting herpes simplex infection. Case report: A 84-year old woman with worsening of her herpes simplex keratitis, diagnosed, and treated 2 days before. The slit lamp showed deep paracentral infiltrate and hypopyon. A corneal sample was collected for culture prior to initiation of empiric antibiotic therapy with vancomycin and ceftazidime fortified, oral acyclovir, and cyclopentolate. The strain was identified as M. nonliquefaciens and topical antibiotic therapy was adjusted to ciprofloxacin and ceftazidime. After 2 weeks, the epithelial defect and the infiltrate were resolved and prednisolone was added to the regimen. As the corneal oedema and neovascularization decreased, acyclovir, and prednisolone were slowly tapered. About 4 months later, the visual outcome was 20/50 and the ophthalmic examination showed a clear cornea with a paracentral leucoma. Conclusion: Keratitis due to M. nonliquefaciens is rare and should be suspected in patients with local predisposing factors such as corneal damage or previous corneal infection. Prompt and appropriate combined treatment for the predisposing lesions and the keratitis may improve the prognosis and avoid a more aggressive approach.


Sign in / Sign up

Export Citation Format

Share Document